ライフサイエンスコーパス: selective drug

1 oxygenase inhibitor as compared with a COX-2 selective drug.

2 F), a non-steroidal anti-inflammatory cancer-selective drug.

3 acilitate the design of new ghrelin receptor-selective drugs.

4 urons and will facilitate the development of selective drugs.

5 l facilitate the development of CRF receptor selective drugs.

6 rs (GPCRs) has the potential to provide more selective drugs.

7 unclear, limiting the development of signal-selective drugs.

8 ing the way to target specific channels with selective drugs.

9 ld aid in the development of more potent and selective drugs.

10 eling neuronal function and developing state-selective drugs.

11 of which are abnormally sensitive to 5-HT2CR-selective drugs.

12 entially be used to design novel and subtype selective drugs.

13 n into consideration when developing subunit-selective drugs.

14 and a determination to develop targeted and selective drugs.

15 an facilitate development of more potent and selective drugs.

16 ecause this will ultimately aid in designing selective drugs.

17 ersity set, and the selective drugs from non-selective drugs.

18 er-soluble, highly potent, and GluA2 subunit-selective drugs.

19 an ideal target for the discovery of subtype-selective drugs.

20 oncoproteins and enable the creation of more selective drugs.

21 te would allow for a broader range of tissue selective drugs.

22 decrease in the affinity of the highly D(4)-selective drug 3-([4-(4-iodophenyl) piperazin-1-yl]methy

23 received microinfusions of the 5-HT receptor-selective drugs 8-OH-DPAT (0.025 or 0.1mug), WAY 100635

24 Selective drug accumulation in adipose tissue has been o

25 e of understanding the mechanisms underlying selective drug action and resistance for the development

26 reshaping drug discovery by enabling pathway-selective drug action.

27 eatment of tumor-bearing animals, with tumor-selective drug activation, producing superior systemic t

28 is article provide a guide for the design of selective drugs against many prokaryotic and eukaryotic

29 drate sulfatases could function as sulfatase-selective drugs, allowing precise control of sulfatase a

30 stigated the 5-year SUD outcomes following a selective drug and alcohol prevention program targeting

31 s the first clinical trial evaluating a GPER-selective drug and the opportunity of repurposing licens

32 ase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras c

33 Competition between PDE5/6-selective drugs and the inhibitory gamma-subunit for the

34 njected dopamine D1- and D2-receptor subtype selective drugs, and then evaluated behavioral responses

35 that the effects of manipulating S100B using selective drugs are a result of changes in neuron and gl

36 More selective drugs are available today, but this therapeuti

37 GABAA receptor subtype-selective drugs are therefore expected to provide novel

38 Highly selective drugs are urgently needed.

39 oinflammatory pathways and suggest PPARdelta-selective drugs as candidate therapeutics for atheroscle

40 nd P2X3, revealing a previously undiscovered selective drug-binding site in the receptor.

41 Gene deletion or selective drug blockade of TRPC6 or cGMP/PKG activation

42 a target site for the development of CaTMPK-selective drugs, but also revealed that 5-FUrd may have

43 er of studies have shown that delta receptor-selective drugs can enhance their potency.

44 which may have therapeutic advantages to MOP-selective drugs, can decrease alcohol drinking in nonhum

45 The development of selective drug candidate molecules for cancer-related ca

46 we characterize a promising novel a5-subunit-selective drug candidate.

47 haracterize a promising novel alpha5-subunit-selective drug candidate.

48 O-Me-cAMP to proximal tubules using a kidney-selective drug carrier approach resulted in prolonged ac

49 ntial for DEAdcCE-caged peptide sequences as selective drug carriers in the context of photocontrolle

50 Tumor-selective drug conjugates can potentially improve the pr

51 c activators and has suggested ways in which selective drugs could be developed to treat them without

52 One strategy to achieve selective drug delivery for EOC therapy involves use of

53 This is the first study of selective drug delivery in humans using a novel PSA-acti

54 t levels of mobile ferrous iron (Fe(II)) for selective drug delivery in vivo.

55 hese problems, there is an urgent need for a selective drug delivery system for PDT PSs.

56 eutically relevant target, as it can provide selective drug delivery to cancer cells.

57 provide an exciting alternative approach for selective drug delivery to tumor cells that may improve

58 This selective drug delivery translates into improved efficac

59 astly, bioimprints also have applications as selective drug delivery vehicles to tumours with the pot

60 ation in various fields of chemical biology, selective drug delivery, and identification of cyclic pe

61 or is a potential molecular target for tumor-selective drug delivery, including radiolabeled folate-c

62 ctivator, to obtain sustained, enhanced, and selective drug delivery, including various sized molecul

63 To increase HER2-positive tumor cell selective drug delivery, we optimized the two most impor

64 or is a potential molecular target for tumor-selective drug delivery.

65 technology was demonstrated by an example of selective drug delivery.

66 tumors is hypoxia, which offers a target for selective drug delivery.

67 penetrating properties, which are useful for selective drug delivery.

68 type, this makes it an attractive target for selective drug delivery.

69 orters, which hold great potential for tumor-selective drug delivery.

70 terial infections and provide new routes for selective drug delivery.

71 g electrodes, transducers for biosensors, or selective drug-delivery.

72 versity could have important implications in selective drug design against a wide range of ERalpha-re

73 t responses will enable novel routes for PTP-selective drug design, important for managing diseases s

74 cations for agonist-directed trafficking and selective drug design.

75 n-competitive inhibitors and is a target for selective drug design.

76 ant differences which could be exploited for selective drug design.

77 Ridinilazole is a highly selective drug designed to treat CDI and prevent rCDI.

78 indings could provide a strategy for pathway-selective drug discovery that is applicable to the diver

79 guanines is not sufficient to explain the GC-selective drug-DNA association, and the implications of

80 eria burden, and then calculate and unlock a selective drug dose.

81 ely useful in the prediction of functionally selective drug effects.

82 re isoform-selective and potentially pathway-selective drugs for human therapy.

83 be a target for developing subtype or state-selective drugs for nAChRs.

84 dings could accelerate the discovery of more selective drugs for the treatment of a variety of neurop

85 icate functional assays intended to identify selective drugs for these receptors is the strong concen

86 es the drugs from the diversity set, and the selective drugs from non-selective drugs.

87 rological conditions, the absence of subtype-selective drugs has hindered adoption of this therapeuti

88 ndings support that NSAIDs and the new Cox-2-selective drugs have an unsuspected target, the B cell,

89 Newer Cox-2-selective drugs have been heavily prescribed to quench i

90 Behavioural investigations using selective drugs have demonstrated that memory formation,

91 effector activity within a group of receptor-selective drugs holds the promise of increased selectivi

92 y and lower toxicity obtained with different selective drugs in respect to non-selective ones, most o

93 s avoid the TRPV1 ligand capsaicin, allowing selective, drug-inducible activation of a specific behav

94 w insight into the mechanism by which gamma8-selective drugs inhibit AMPARs.

95 ndescribed strategy for the design of highly selective drug inhibitors involving ligands that wrap no

96 n and stool consistency, and targeted 5-HT4R selective drug intervention has been proven beneficial i

97 r ~25% of approved drugs, developing subtype selective drugs is a major challenge due to the high seq

98 immunity, the recruitment of this pathway by selective drugs is expected to attenuate the autoimmune

99 IIalpha, the primary target of many leukemia selective drugs, is low.

100 Hitherto, the vast majority of selective drug leads that have been developed for KOR ar

101 ctures of human Sirt2 in complex with highly selective drug-like inhibitors that show a unique inhibi

102 we disclose the identification of potent and selective drug-like pan-BD2 inhibitors such as pyrazole

103 d discusses two recent 5-HT receptor subtype-selective drugs, lorcaserin and pimavanserin, which targ

104 Therapeutically, selective drugs may improve the safety profile of benzod

105 together with the development of new subtype-selective drugs, may provide more specific and effective

106 and indicate that the development of circuit-selective drugs might alleviate sleep disorders with few

107 Previous work suggested that subtype-selective drugs might allow separating desired antihyper

108 tion of AMPAR or KAR signaling and that more selective drugs might maintain antiseizure efficacy whil

109 Selective drug modulation of either TRPV1 activity or it

110 y allow the generation of potent highly TSHR-selective drugs, of potential value for the treatment of

111 , particularly the discovery of TARP subtype-selective drugs, offer the exciting potential to modify

112 Moreover, designing selective drugs often benefits from the targeting of div

113 lt to identify, and attempts to develop more selective drugs on the basis of the action of glucocorti

114 lly, due to the lack of sufficiently subtype-selective drugs or high avidity antibodies, the contribu

115 us anatomic spaces that together promote CNS selective drug partition.

116 populations of cancer cells can evade strong selective drug pressure by entering a 'persister' state

117 HIV drug resistance does not emerge if selective drug pressure is not present, so some exposure

118 establish latency and reactivate absent any selective drug pressure is unknown and has implications

119 or selection of these silent mutations under selective drug pressure is unknown.

120 ainst influenza A (H1N1) viruses by applying selective drug pressure over multiple sequential passage

121 Under selective drug pressure, I50V/L substitutions emerge in

122 e-half of HIV-1 protease positions are under selective drug pressure, including many residues not pre

123 iated amino acid substitutions are caused by selective drug pressure, including substitutions not pre

124 The sequences of these genes, unaffected by selective drug pressure, were monophyletic.

125 nt of HIV-1 proteinase that has arisen under selective drug pressure.

126 iting, and identify mutations resulting from selective drug pressure.

127 resistance (TDR) mutations in the absence of selective drug pressure.

128 ery low detection threshold until exposed to selective drug pressure.

129 thus cannot emerge rapidly in the absence of selective drug pressure.

130 s, but that the NSAID indomethacin and Cox-2-selective drugs profoundly inhibit the ability of human

131 t chemoattraction were inhibited by the mTOR-selective drug rapamycin.

132 rugs with distinct mechanisms of action with selective drug release and convection-enhanced delivery

133 obalt-chaperone moiety, we have demonstrated selective drug release in the acidic and hypoxic tumor m

134 odal therapies of cancer by promoting tumour-selective drug release.

135 ell sorting and mass spectrometry confirming selective drug retention in beta-cells over non-beta-cel

136 address this, we integrated the data from a selective drug screen in epithelial and mesenchymal KRAS

137 le Cdc25C and PP2Acalpha phosphatases in the selective drug sensitivity of del(5q) MDS.

138 s received microinfusions of the DA receptor-selective drugs SKF 81297 (0.1 or 0.4microg), SCH 23390

139 and TMS10 mutations can also induce total or selective drug susceptibility.

140 suggests that dUTPases may also represent a selective drug target in mycobacteria because of the cru

141 highlights the MEP pathway's potential as a selective drug target, which is absent in humans but ess

142 1-AR interaction offers a functionally tumor-selective drug target.

143 n case studies for predicting and explaining selective drug-target interactions.

144 y demonstrates a proof of concept for tissue-selective drug targeting based on G protein-coupled rece

145 tility of a purely chemical means to achieve selective drug targeting in vivo.

146 This study provides proof of concept for selective drug targeting of proximal tubular cells on th

147 Selective drug targeting of this osteoblast signaling pa

148 Here, we combined synthetic lethality with selective drug targeting to identify multi-target and or

149 ghts that are potentially useful for isoform-selective drug targeting.

150 P/ATP carriers, suggesting opportunities for selective drug targeting.

151 ructure of P2X receptors, efforts to develop selective drugs targeting P2X3 have led to the developme

152 by paving the way for the development of new selective drugs targeting the amyloidogenic proteins imp

153 Mutant selective drugs targeting the inactive, GDP-bound form o

154 ictions provide new opportunities to develop selective drug targets for prostate cancer and other can

155 d nitrogen distribution as potential species-selective drug targets in M. tuberculosis.

156 s more readily inhibited by NSAIDs and COX-2-selective drugs than COX-1 in platelets (e.g., log IC50+

157 d qualitatively different than those of less selective drugs that act at D2-like or serotonin (5-HT)1

158 Other, allegedly more selective drugs that affect leukocyte recruitment in the

159 The discovery of functionally selective drugs that are therapeutically effective witho

160 pockets that may support the development of selective drugs, the application of advanced techniques

161 of many serotonin receptor subtypes enables selective drugs to be designed to therapeutically modula

162 ls were superfused with a variety of GABA(A)-selective drugs to determine their effects on [Ca(2+)](i

163 for directed design of new, more potent and selective drugs to develop an efficient treatment for Ch

164 in mouse hippocampus and with novel isoform-selective drugs to dissect their roles in LTD.

165 The search for more effective and selective drugs to overcome cancer multidrug resistance

166 ligands may lead to the development of more selective drugs to treat obesity or addiction with minim

167 enotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to

168 nanoarchitectural alterations, we performed selective drug treatment on the specific cytoskeletal co

169 ain benzoyl group is not essential for tumor-selective drug uptake by FRalpha.

170 s been a long standing goal in the design of selective drugs useful in implicated diseases for this p

171 Using recently developed selective drugs, we show that ATR inhibition has a signi

172 The most AF-selective drugs were associated with minimal ventricular

173 akes it difficult to predict whether subtype-selective drugs will have an improved efficacy and side-

174 This work supports the hypothesis that M4-selective drugs will prove useful to control the functio

175 Selective drugs with a relatively narrow spectrum can re

176 exes provides an opportunity to develop more selective drugs with fewer side effects.

177 ctedly and in contrast to all previous mGlu7-selective drugs, XAP044 does not act via the seven-trans

178 38,417 was effective, but the alpha1-subunit-selective drug zolpidem exacerbated social deficits.